The 1886 American pharmaceutical landscape into which Coca-Cola was introduced bore essentially no resemblance to the regulated drug-approval system that has governed American medicine since the passage of the Pure Food and Drug Act in 1906 and the establishment of the Food and Drug Administration in subsequent decades. The patent medicine industry of the late 19th century operated, by modern standards, in a legal vacuum. There were no requirements for ingredient disclosure, no clinical trial standards, no truth-in-advertising regulations, and no restrictions on the inclusion of substances that the 20th century would classify as controlled or illegal narcotics. Patent medicines routinely contained cocaine, heroin, morphine, alcohol, mercury, arsenic, cannabis tincture, and assorted plant alkaloids of variable purity and dosage, sold over the counter at any drugstore, advertised in newspapers as cures for whatever ailment the manufacturer cared to specify. Pemberton, by every reasonable contemporary standard, was working within an established and uncontroversial commercial tradition.
According to Smithsonian Magazine’s account of the Coca-Cola origin story and Pemberton’s personal medical history, the specific motivation for the Coca-Cola formula was Pemberton’s own ongoing struggle with morphine addiction, which had developed during his postwar convalescence and had persisted across the intervening two decades. Like many Civil War veterans of his generation, Pemberton had been prescribed morphine for pain management during the chronic-injury phase of his recovery and had subsequently been unable to discontinue the drug. By the early 1880s, he was actively reading the contemporary medical literature on possible morphine-addiction treatments, and in particular, the work of European physicians who had begun suggesting — on the basis of substantially overstated initial clinical reports — that cocaine, the active alkaloid recently isolated from the South American coca plant, might function as a safe substitute for morphine that would allow addicted patients to taper off the more dangerous opioid. The proposition that one addictive stimulant could be used to treat addiction to another was, in the early 1880s pharmacological literature, considered medically plausible. The substantial empirical evidence that emerged across the subsequent two decades — demonstrating that cocaine simply added a second addiction to the first — was not yet available to Pemberton or to the broader patent medicine industry.
From French Wine Coca to Coca-Cola
Pemberton’s first major attempt at a morphine-substitute beverage was a product he registered in 1885 at his Pemberton’s Eagle Drug and Chemical House in Columbus, Georgia, called Pemberton’s French Wine Coca. The formula was modeled directly on Vin Mariani — a popular French tonic, manufactured by the Corsican chemist Angelo Mariani, that combined Bordeaux wine with coca-leaf extract and that had been endorsed by Pope Leo XIII, Queen Victoria, Thomas Edison, the Russian Tsar, and most of the medical establishments of the late-19th-century European capitals. Vin Mariani was, in essential respects, the most famous and most widely-consumed patent medicine in the Western world during the 1880s. Pemberton’s French Wine Coca was an American adaptation of the same formula, combining alcoholic wine with coca leaf, kola nut (a natural source of caffeine), and the herb damiana, marketed as a nerve tonic cure-all. As detailed in Pharmacy Times’s biographical summary of Pemberton’s career and the development of the Coca-Cola formula, the product was successful enough commercially that Pemberton was, by 1886, planning to expand its distribution from Columbus to Atlanta and beyond.
The intervention that produced the Coca-Cola formula specifically was the November 1885 enactment by Atlanta and Fulton County of a local temperance prohibition law, which forbade the sale of alcoholic beverages within the county’s jurisdiction for a two-year period beginning in July 1886. Pemberton, whose distribution plans depended on Atlanta, was forced to remove the alcohol from French Wine Coca. He substituted sugar for the wine, added citric acid to counteract the bitterness produced by the substitution, and combined the resulting non-alcoholic syrup with carbonated water at the soda fountain at Jacob’s Pharmacy — producing, by happy accident, a beverage that tasted substantially better than its alcoholic predecessor and that worked particularly well in the soda fountain format that was, in 1886, becoming the dominant retail channel for non-alcoholic refreshment in American urban centers. The new product needed a new name. Pemberton’s bookkeeper, Frank Mason Robinson, suggested “Coca-Cola” — selecting the alliterative repetition of the letter C for visual distinctiveness in printed advertising, and writing out the now-famous Spencerian-script logo by hand. The first glass was sold on 8 May 1886. Average sales for the first year amounted to approximately nine glasses per day.
What Pemberton thought he was selling
The marketing copy Pemberton produced for Coca-Cola during the period he personally controlled the company — May 1886 through approximately mid-1888, when his deteriorating health forced him to begin selling off the business — explicitly framed the product as a patent medicine. As described in a recent retrospective on the 140th anniversary of Coca-Cola’s first sale and its original therapeutic positioning, advertisements ran in the Atlanta Journal and other regional newspapers describing the beverage as effective against morphine addiction, dyspepsia, neurasthenia (a vague catch-all 19th-century diagnostic category covering chronic fatigue, anxiety, and assorted unspecified nervous complaints), headaches, nausea, exhaustion, and impotence. The target demographic was explicitly the urban professional class — “ladies, and all those whose sedentary employment causes nervous prostration,” in the language of one early advertisement — who were assumed to be the most reliable consumers of such products in the broader patent-medicine market.
The cocaine content of the original Coca-Cola formula was real but small. Each glass of the original beverage contained approximately 9 milligrams of cocaine — substantially less than the 50 to 100 milligrams that constituted a typical contemporary medicinal cocaine dose, but sufficient to produce a measurable mild stimulant effect when consumed in the larger quantities common at soda fountains. The cocaine was reduced progressively across the early 20th century as public attitudes toward the drug shifted from medical enthusiasm to public-health concern, and was effectively removed from the formula by 1903, when the Coca-Cola Company began using “spent” coca leaves from which the cocaine alkaloid had been extracted in advance. The final traces were removed by 1929. As reported by a recent reconstruction of Pemberton’s tragic personal trajectory through the founding period of Coca-Cola, Pemberton himself did not live to see any of this. His morphine addiction worsened across 1887 and 1888. His financial situation deteriorated. He sold his interest in the company in pieces to multiple Atlanta business partners, finalising the transfer of his remaining ownership share to a sharp Atlanta businessman named Asa Griggs Candler for approximately $2,300 (roughly $80,000 in current purchasing power) shortly before his death from stomach cancer in August 1888. Candler stripped the patent-medicine framing from the marketing, reframed the product as a soda fountain treat, and built the brand into the global beverage business it remains today — now selling approximately 1.6 billion servings per day across essentially every country on Earth, the most successful commercial accidental byproduct in the history of the American pharmaceutical industry, and a 138-year-old monument to the proposition that a failed attempt to cure one specific person’s morphine addiction can, with appropriate marketing and the right business successor, become the most widely consumed beverage on the planet outside of water and tea.
